What is the treatment for Sjögren’s syndrome?

Treatment of Sjögren's Syndrome

Treatment of Sjögren's syndrome should be stratified based on whether the patient has primarily glandular symptoms (dryness) or active systemic disease, with glandular dysfunction managed by stimulation or substitution based on residual salivary function, and systemic manifestations requiring immunosuppressive therapy. 1

Management Framework

The 2020 EULAR guidelines provide a structured, algorithmic approach starting with the "central triplet" of symptoms (dryness, fatigue, pain) followed by systemic manifestations 1.

---

Glandular Manifestations

Oral Dryness

Baseline salivary gland function measurement is mandatory before initiating treatment - therapeutic decisions should be driven by objective glandular function, not subjective symptoms alone 1.

Mild Glandular Dysfunction (Residual Function Present)

• First-line: Non-pharmacological stimulation 1
  • Sugar-free acidic candies, lozenges, xylitol
  • Sugar-free chewing gum
  • Preparations should have neutral pH and contain fluoride

Moderate Glandular Dysfunction

• Muscarinic agonists (pilocarpine or cevimeline) 1
  • Reserve for patients with moderate dysfunction OR those with mild dysfunction refractory to non-pharmacological measures
  • Pilocarpine is licensed worldwide; cevimeline has better tolerability profile but limited availability
  • Important caveat: High frequency of adverse events limits use; evidence in primary Sjögren's patients meeting 2002 criteria is limited

Severe Dysfunction (No Salivary Output)

• Saliva substitutes (oral sprays, gels, rinses) 1

Ocular Dryness

Step-wise escalation algorithm 1:

Step 1: First-Line

• Artificial tears containing methylcellulose or hyaluronate at least twice daily, up to hourly as needed
• Preservative-free formulations if ≥4 applications daily
• Ophthalmic ointments at bedtime for overnight symptom control (followed by morning lid hygiene to prevent blepharitis)

Step 2: Refractory/Severe Cases

Sequential escalation if no response/intolerance:

1. Topical corticosteroids (short-term only: 2-4 weeks maximum) 1
2. Topical cyclosporine A
3. Serum eye drops
4. Rescue therapies: Punctal plug insertion, oral muscarinic agonists

Critical warning: Prolonged topical NSAIDs or corticosteroids risk corneal-scleral melts, perforation, ulceration, infections, and increased intraocular pressure 1.

---

Systemic Disease

When to Use Systemic Immunotherapy

Systemic immunomodulatory/immunosuppressive therapy should be restricted to patients with active systemic disease after careful organ-by-organ evaluation of severity and damage 1. Not all patients with active systemic disease require systemic therapy.

Treatment Strategy

Two-stage sequential regimen 1:

1. Induction phase: Intensive immunosuppression to restore organ function rapidly
2. Maintenance phase: Sustain therapeutic response

Duration must be decided case-by-case due to lack of specific evidence in Sjögren's.

Specific Agents

Mild-Moderate Systemic Disease

• Hydroxychloroquine 1, 2
• Leflunomide, iguratimod, or tripterygium glycosides (particularly in Chinese practice) 2
• Low-dose recombinant human IL-2 2

Severe/Refractory Systemic Disease

• Rituximab (B-cell depletion) 1, 2
• Cyclophosphamide 1, 2
• Mycophenolate mofetil 1, 2
• Glucocorticoids (for acute severe manifestations) 1
• Azathioprine, methotrexate 1

Emerging Therapies (Promising but Not Yet Standard)

Recent phase 3 trials show positive results for ianalumab and telitacicept (B-cell targeted therapies), along with FcRn inhibitors (nipocalimab, efgartigimod) showing consistent ESSDAI reduction 3, 4.

---

Special Populations

Pregnant Patients with Anti-SSA Antibodies

Require multidisciplinary care and close monitoring for congenital heart block risk 2. Treatment must balance maternal disease control with fetal safety.

---

Common Pitfalls

1. Treating based on subjective dryness alone without objective glandular function assessment leads to inappropriate therapy selection 1

2. Prolonged topical corticosteroid/NSAID use for ocular symptoms risks serious complications including perforation 1

3. Using systemic immunosuppression for sicca symptoms alone - reserve for true systemic disease activity 1

4. Failing to rule out SjS-unrelated conditions (candidiasis, burning mouth syndrome) before treating oral symptoms 1

5. Not considering preservative-free artificial tears in patients requiring frequent dosing (≥4 times daily) 1